This Section is for those who are interested in following research into Parkinson's and thinking about what questions remain unanswered, what issues need to be resolved and what implications arise from research results.
Below are topics which contributors wish to bring to the attention of others.
|
But there is also a 'Magazine Section' dealing with articles to enable readers to get an overview of the current 'Hot Topics' and read discussions of key issues. These articles will link to the main body of the learning project.
|
|
Purpose of Section 1:
To enable contributors:
- to highlight interesting topics in current Parkinson's research
- to explain their significance and background
- to describe the questions answered and identify the questions still unanswered
- to say how the work fits into the bigger picture and what other researchers are doing
- to examine hypotheses and to raise implications
- to identify possible new lines of enquiry and new implications for research strategy
|
Topics below in red are those thought to be important but have not been worked on yet. You are invited to start them.
You are welcome to add topics you believe are important.
Topics for Progress and Prospects in Parkinson's Research
| Main field |
Topic |
Subpages
|
| Researching Parkinson's |
Modelling PD |
Animal Models, Rotenone Model, Induced Pluripotent Stem Cells, A pathogenesis map
|
|
Hot Topics |
Vitamin D, Role of alpha-synuclein in pathogenesis, Neuroprotective agents, Biomarkers and Biomeasures, Induced Pluripotent Stem Cells, Genome-Wide Association Studies, Getting Drugs from Lab to Clinic
|
| Causes |
Inheritance |
SNCA,
LRRK2,
MAPT,
GBA,
HLA
|
|
Trauma |
Cysts,
Vascular PD,
|
|
Infection |
Helicobacter pylori,
Influenza,
Lipopolysaccharide,
Melanoma,
Whooping cough,
|
|
Deficiencies |
Blood,
Glutathione,
Melatonin, Norepinephrine, Vitamin D,
Zinc
|
|
Toxins |
Cadmium,
Copper,
Dieldrin,
Manganese,
Maneb,
Mercury,
MPTP,
n-Hexane,
Paraquat,
Rotenone,
Toluene,
Trichloroethylene,
Ziram,
|
| Pathogenesis |
Current Parkinson's Paradigm |
Working Hypothesis, Emerging Hypotheses, Oxidative Stress, Inflammation, Role of alpha-synuclein, A pathogenesis map
|
| Symptoms |
|
| Therapy |
Transplantation
|
|
Symptomatic Relief |
Bradykinesia -,
Dyskinesia -,
Festination -,
Freezing -,
Non-motor symptoms -
Sleep Disturbance -,
Tremor,
|
|
Exercise |
Effect on symptoms, Neuroproective effects
|
|
Neuroprotection |
Neuroprotective agents,
Caffeine,--
Celastrol,--
Co-enzyme Q10,--
Creatine,--
DHA,--
Exendin-4 (EX-4),--
GDNF,--
Glutathione (GSH),--
GM1,--
Herbal Remedies,--
Isradipine,--
Melatonin,--
Mirapex,--
Minocycline,--
Nicotine,--
NSAIDs,--
Phenylbutyrate,--
Phytic Acid,--
Probucol,--
Quinoxaline,--
Rasagiline,--
Riboflavin,--
Statins,--
Tolcapone,--
Urate & Uric Acid--
Vitamin D,--
Vitamin E,--
|
|
Gene Therapy |
RNA interference
|
|
From Lab to Clinic |
Clinical trials and the route to market
|
| Monitoring Disease |
Biomarkers, Measurement of Disease Progression
|
| Atypical parkinsonism |
MSA, PSP, DLB, ET, CBD,
|
